The Chairman, Chief Executive Officer (CEO), Elipse Industries, Mr. Denzel Henry Akogwu and his entire staff has congratulated Engr. Mustapha M. Yusuf who retired from the Federal Civil Service as a ...

The two souls of Ljubljana merge in a new residential building In the two elevations of the Elipse building – an exact curve and a tormented series of wave-like terraces – the Austro-Hungarian rigor ...

This study is comparing 2 different types of routine surgery for prostate cancer that has a high risk of coming back.

Enrollment continues in dose escalation phase of ELiPSE-1 at dose levels 3B (three weekly infusions of 1 billion cells) and 4A (single infusion of 3 billion cells) per cycle PHILADELPHIA, June 03, ...

EX103: A newly designed CD20×CD3 molecule in heavily pre-treated patients with B-cell non-Hodgkin lymphoma from a phase I/II trial. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I ...

ZUMA-22: A phase 3, randomized controlled study of axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed or refractory (R/R) follicular lymphoma (FL). This is an ...

Medical consultation. General practioner measuring the waist of an obese patient. Investigators reviewed the effects of the Elipse intragastric balloon on weight loss, waist circumference, metabolic ...

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload ...

Dezeen Showroom: Spanish designer Josep Lluís Xuclà has designed a "magical" outdoor light for Marset, which creates the illusion of floating and glowing from within. Called Elipse, it consists of a ...

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, a pioneering leader in the development of innovative, scalable and trusted weight loss experiences, today announced new clinical data on the ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. The medical device company is conducting a late-stage trial ...